We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: Horiba Medical at the EUROMEDLAB 2022 (Photo courtesy of Horiba Medical)
Image: Horiba Medical at the EUROMEDLAB 2022 (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) showcased its hematology and hemostasis solutions at the EUROMEDLAB 2022 which took place from April 10 to 14 at the ICM Internationales Congress Center, Munich, Germany. The company also presented scientific posters on its high range hematology solutions during the poster session time.

At its exhibition booth, Horiba showcased its automation high-end HELO Global Hematology Solution covering all the needs of a high throughput automated hematology platform. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses all the needs of laboratories, but helps to optimize their TAT, floor space and reagent storage. Among its Yumizen range of hematology solutions, Horiba displayed its Yumizen H2500/H1500 and the Yumizen H550 hematology analyzers. The Yumizen H2500/H1500 has a real throughput of 120 samples per hour for CBC-DIFF NRBC and slides and come with on board reagents (5 for Yumizen H2500 and 4 for Yumizen H1500). Along with testing for up to 55 parameters, their automatic 360°C rotative sample mixing provides perfect homogeneity. On the other hand, the Yumizen H550 is a compact 6-diff hematology analyzer with an auto sampling system which aims at providing a full walk away capability to a variety of clinical environments: hospitals, satellite labs, emergency care, small independent labs, and doctors’ offices.

Among its Yumizen range of hemostasis solutions, Horiba displayed its Yumizen G1550/G1500 and Yumizen G400 hemostasis analyzers. The Yumizen G1550/G1500 automated analyzer offers routine and specialized testing in a single analysis system along with liquid and ready-to-use reagents for 80% of laboratory activity. It offers up to eight measuring channels with two wavelength combinations, continuous loading, and simplified anteriority management thanks to a large database of 1,000,000 results. The Yumizen G400 semi-automated hemostasis analyzer offers four independent measuring channels and 20 incubation positions and is easy to operate with an innovative user interface. Other solutions on display at the Horiba EUROMEDLAB 2022 exhibition booth included the Yumizen SPS slide maker, the CellaVision DC-1 digital cell morphology system, the Yumizen P8000 middleware and expert validation station and the Yumizen T6000 automated conveyor.

Related Links:
Horiba Medical 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.